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Boosting of ALVAC-SIV Vaccine-Primed Macaques with the
CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2
Associated with a Decreased Risk of SIVmac251 Acquisition
Shari N. Gordon,* Namal P. M. Liyanage,* Melvin N. Doster,* Monica Vaccari,*
Diego A. Vargas-Inchaustegui,† Poonam Pegu,* Luca Schifanella,* Xiaoying Shen,‡
Georgia D. Tomaras,‡ Mangala Rao,x Erik A. Billings,x Jennifer Schwartz,{
Ilia Prado,{ Kathryn Bobb,{ Wenlei Zhang,{ David C. Montefiori,‡ Kathryn E. Foulds,‖
Guido Ferrari,‡ Marjorie Robert-Guroff,† Mario Roederer,‖ Tran B. Phan,#
Donald N. Forthal,# Donald M. Stablein,** Sanjay Phogat,†† David J. Venzon,‡‡
Timothy Fouts,{ and Genoveffa Franchini*
The recombinant ALVAC vaccine coupled with the monomeric gp120/alum protein have decreased the risk of HIV and SIV
acquisition. Ab responses to the V1/V2 regions have correlated with a decreased risk of virus acquisition in both humans and
macaques. We hypothesized that the breadth and functional profile of Abs induced by an ALVAC/envelope protein regimen could
be improved by substituting the monomeric gp120 boost, with the full-length single-chain (FLSC) protein. FLSC is a CD4-gp120
fusion immunogen that exposes cryptic gp120 epitopes to the immune system. We compared the immunogenicity and relative
efficiency of an ALVAC-SIV vaccine boosted either with bivalent FLSC proteins or with monomeric gp120 in alum. FLSC was
superior to monomeric gp120 in directing Abs to the C3 a2 helix, the V5 loop, and the V3 region that contains the putative CCR5
binding site. In addition, FLSC boosting elicited significantly higher binding Abs to V2 and increased both the Ab-dependent
cellular cytotoxicity activity and the breadth of neutralizing Abs. However, the FLSC vaccine regimen demonstrated only a trend
in vaccine efficacy, whereas the monomeric gp120 regimen significantly decreased the risk of SIVmac251 acquisition. In both
vaccine regimens, anti-V2 Abs correlated with a decreased risk of virus acquisition but differed with regard to systemic or
mucosal origin. In the FLSC regimen, serum Abs to V2 correlated, whereas in the monomeric gp120 regimen, V2 Abs in rectal
secretions, the site of viral challenge, were associated with efficacy. The Journal of Immunology, 2016, 197: 2726–2737.
A
protective role of vaccine-induced Abs has been sug-
gested by the correlate analysis of the RV144 Thai trial,
the first phase III clinical trial to show partial efficacy.
Vaccination with the canarypox vector ALVAC expressing HIV
gag-pro and gp120-TM genes and bivalent gp120 proteins
(AIDSVAX B/E) formulated in alum significantly reduced the risk
of HIV infection with an estimated efficacy rate of 31.2% (1).
Reduced HIV risk was primarily associated with Abs directed to
the V1/V2 region of gp120, whereas Abs that mediated other
functions, including Ab-dependent cellular cytotoxicity (ADCC),
were correlates in secondary analyses (2, 3). The results of the
Thai trial have engendered optimism in the HIV vaccine field;
however, the efficacy of the ALVAC/gp120 vaccine regimen needs
to be augmented.
Neutralizing Abs are an effective antiviral response, and when
passively administered systemically or mucosally, they can prevent
simian HIV intravaginal infection (4–6). Nonneutralizing Abs are
readily induced by many vaccination regimens and can coordinate
with innate effector cells to opsonize virus or kill infected cells.
Multifunctional Abs that mediate ADCC, phagocytosis, or Ab-
dependent cell-mediated viral inhibition have been associated
with vaccine-induced protection from infection, reduced virus
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transmission, and virus control post SIV/HIV infection (3, 7–14).
Thus, strategies that alter the breadth and/or the functional ca-
pacity of the Ab response may provide increased clinical benefits.
HIV binding and entry into target cells is a two-step process:
binding to CD4 induces a conformational change in gp120 that
brings together several variable and constant regions forming the
coreceptor binding site. Coreceptor binding then facilitates virus
entry (15). The CD4-induced conformational change in gp120
reveals conserved intermediate structures that are presented tran-
siently to the immune system before virus-target cell fusion (16).
These conserved moieties are antigenic and can be divided into
three epitope clusters: A, B, and C (17). Cluster A epitopes are
occluded by gp41 in envelope trimers and become exposed during
entry. They are functional targets for ADCC and include the A32-
directed conformational epitope in the C1 region of gp120 (18,
19). Cluster B and C epitopes are proximal to or include the
coreceptor binding site. They are absent, occluded, or only min-
imally displayed on monomeric or trimeric gp120. Cluster B
epitopes are also ADCC targets. Cluster C epitopes induce Abs
with a range of neutralization potency and breadth, and include
broadly neutralizing Abs like 17b (20). Interestingly, CD4 induced
epitopes (CD4i) can also be formed on the surface of cells when
recently synthesized envelope proteins interact with CD4 (19).
Because these structures represent a possible Achilles heel for
HIV, the virus has evolved a strategy to minimize their exposure
by downregulating CD4 from the surface of HIV-infected cells
through the function of the Nef and Vpu proteins (19).
The full-length single-chain (FLSC) protein was generated by
fusing gp120 with a flexible linker and CD4 to allow the gp120/CD4
interaction and exposure of cryptic epitopes (21). Furthermore,
FLSC induced Abs to CD4i epitopes were associated with accelera-
ted simian HIV control in nonhuman primate studies (22). Re-
cently, a DNA prime-FLSC protein boost vaccination regimen
reduced the rate of SIVmac251 mucosal acquisition (23). Thus,
our goal was to test whether in macaques, the protective efficacy
of an RV144-like regimen using an ALVAC-SIV prime and a
protein boost could be improved by inducing Abs to CD4i epi-
topes. Thus, we directly compared the Ab and cell-mediated im-
mune response in ALVAC-SIV primed animals, boosted with
either monomeric gp120 (24) or FLSC proteins. We found that
although the nature of the protein boost significantly altered Ab
responses, it had no impact on the T cell response and surprisingly
did not improve vaccine efficacy against repeated intrarectal low
doses of SIVmac251. However, both vaccination regimens induced
V2-directed Abs that were associated with delayed SIV acquisition.
Materials and Methods
Animals, vaccination, and SIV challenge
Seventy-seven rhesus macaques (Macaca mulatta) of Indian origin were
used in this study. All animals were housed and cared for under the
guidelines of the Association for the Assessment and Accreditation of
Laboratory Animal Care. The study was conducted with the approval of
the Institutional Animal Care and Use Committee at Advanced BioSci-
ences Laboratories (Rockville, MD).
Fifty-three animals were vaccinated in the quadriceps at weeks 0, 4, 12,
and 24 with 108 PFU of ALVAC (vCP2432) expressing SIV genes gag-pro
and gp120 transmembrane (TM) domain manufactured by Sanofi Pasteur
(Fig. 1). The sequence of the SIV genes was obtained from a mucosally
transmitted founder variant of SIVmac251 designated M766 (25). The gag-
pro gene was codon optimized and constructed using human codon bias
leaving the stem loop and slippery sequences intact to allow for the 21
frameshift required for pol translation. The gag-pro encoded the entire gag
followed by pol through the end of the protease. The gp120TM gene was
codon optimized and constructed using human codon bias. The native
signal peptide was replaced with a synthetic signal based on the human
tissue plasminogen activator signal peptide (MDAMKRGLCCVLLLC-
GAVFVTTTEA). The SIVM766 gp120 included the stretch from isoleucine
at position 20 to arginine at position 527 and the 22-aa residue of the gp41
TM domain from tyrosine 695 to leucine 716, following the numbering
based on SIVmac251. Six residues of the HIV-1LAI cytoplasmic tail, as-
paragine 706 to glycine 711, within the TM domain (numbering based on
HIV-1HXB2 numbering convention) were added.
At weeks 12 and 24, 27 animals were given a bivalent monomeric gp120
protein boost, formulated in alum, containing 200 mg of the SIVmac251-
M766 protein and 200 mg of protein from a mucosally transmitted founder
variant of SIVsmE660 designated CG7V, as previously described (Fig. 1)
(24, 26). In brief, monomeric gp120 proteins were produced from Chinese
Hamster Ovary cell lines stably transfected with plasmid DNA. Codon-
optimized genes expressing M766 gp120, I20-R527, and CG7V gp120,
V23-R527 (numbering based on SIVmac251) were inserted into the ex-
pression plasmid pSWTIPK3 following the 53 amino-terminal residues of
the HSV-1 glycoprotein D (gD). Upon processing at the predicted cleavage
site of the HSV-1 leader the gp120s are composed of the 28-residue gD N
terminus, an alanine and serine linker, and the full-length gp120. Plasmids
contain the CMV promoter for gp120 expression and an IRES puromycin-
acetyltransferase cassette for selection of stable clones using the antibiotic
puromycin. Monomeric gD-gp120 proteins were purified at Advanced
BioScience Laboratories (Rockville, MD) by lectin affinity chromatogra-
phy using Galanthus nivalis lectin agarose (Vector Laboratories, Burlin-
game, CA) and anion exchange chromatography using Q-Sepharose fast
flow (GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire, U.K.)
in flow-through mode.
Twenty-six ALVAC-SIV–vaccinated animals were boosted with rhesus
FLSC (rhFLSC) proteins at weeks 12 and 24 (Fig. 1). The FLSC boost also
consisted of M766 and CG7V gp120 proteins formulated in alum, but the
gp120 proteins were linked to the D1D2 domains of rhesus CD4 by a 20-aa
flexible linker that allowed self-association of gp120 and the CD4 mole-
cule. The FLSC proteins were manufactured by Profectus Bioscience and
are described later. The week 12 protein boosts consisted of 200 mg of
FLSC-M766 and 200 mg of FLSC-CG7V. Similarly, at 24 wk, all animals
were given 200 mg of FLSC-CG7V; however, because of manufacturing
problems at week 24, a mixture of FLSC-SIVmac proteins were given:
50 mg of M766 along with 150 mg of SIVmac239 protein.
Vaccinated animals were compared with 47 controls including 23
historical controls that were exposed by the same operators to the same
dose of the same virus stock in the same animal facility, and 24 con-
temporaneous controls that were either naive or given adjuvants (24).
Four weeks after the last immunization, all vaccinated animals and
controls were challenged with SIVmac251 via the rectal route at a dose of
120 TCID50 (Fig. 1A). Animals that tested negative for SIV RNA in
plasma were rechallenged, and a maximum of 10 weekly challenges was
administered.
rhFLSC protein production and formulation
Expi293F cells were transfected with pCDNA5 FRT TO plasmids
expressing either codon-optimized M766, SIVmac239, CG7V gp120, or
FLSC using the Expi293 expression system (Life Technologies). The HSV-
1 gD was not added to these constructs. Media were collected and clarified
by centrifugation at 4 d posttransfection. The FLSCs from the clarified
supernatants were purified using lectin agarose from Galanthus nivalis
(snow-drop; Vector Labs, Burlingame, CA). All steps were performed at 4˚C.
In brief, 16-mm columns containing 20 ml of lectin agarose were equili-
brated with 60–80 ml of sterile filtered buffer A (0.65 M NaCl, 0.25%
Empigen BB [Sigma] in 13 PBS) until the UV absorbance trace at 280 nm
reached baseline. The clarified supernatants were adjusted to 0.65 M NaCl
plus 0.25% Empigen BB, sterile filtered through a 0.22-mm filter, and loaded
onto the lectin agarose columns overnight. After samples were loaded onto
the columns, 20–30 ml of buffer A was added and the flow-through was
collected until the UV absorbance trace decreased to baseline. The columns
were washed four consecutive times with 40 ml each of sterile filtered buffer
B (0.25% Empigen BB in 13 PBS), buffer C (13 PBS), buffer D (1 M of
NaCl in 13 PBS), and then buffer C again. Buffer E (1 M of methyl a-D-
mannopyranoside [MP Biomedicals, Sana Ana, CA] in 13 PBS) was added
to the columns and allowed to flow through until the void column volume
was reached and the UV absorbance increased (∼10–15 ml). The columns
were allowed to sit for 30–60 min in the buffer E before elution of the FLSCs
with an additional 20–40 ml of buffer E. The eluted proteins were then di-
alyzed 33 in 2 l for $4 h each time in 10,000 MWCO Slide-A-Lyzer di-
alysis cassettes (Thermo Fisher). The proteins were then concentrated to 1–3
mg/ml in Amicon Ultra-15 with Ultracel-10 centrifuge filters (10,000 MWCO;
Thermo Fisher).
The purified FLSC proteins were formulated with 20 mg/ml aluminum
phosphate (Alum; Catalent Pharma Solutions,Middleton,WI) at a protein/alum
ratio of 1:8 in 5 mM acetate buffer (pH 5.1) with 40 mg/ml D-mannitol, pH 6.2.
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SIV viral load
Plasma SIV RNA was quantified by nucleic acid sequence-based ampli-
fication as previously described (27). SIV DNA was quantified in mucosal
tissues 3 wk post SIV infection by a real-time quantitative PCR assay with
sensitivity of 10 copies/106 cells as previously described (28). In brief,
genomic DNA was extracted from the rectal biopsies with the DNeasy
Blood & Tissue kit (Qiagen) according to the manufacturer’s protocol as
previously described (29). The quantity and quality of the DNA were
assessed by OD260 measurements using an ND-1000 spectrophotometer
(NanoDrop). The TaqMan probe and PCR primers for the real-time PCR
were designed within the conserved gag gene of SIVmac239, and probe and
primer sequences were also used for monkey albumin gene detection. The
reaction conditions were as follows: the PCR mixture consisted of 500 ng
of genomic DNA extracted from tissues; 200 nM of primers; 100 nM of
probe; 23 TaqMan Universal PCR Mastermix (Applied Biosystems)
consisting of 10 mM of Tris-HCl (pH 8.3); 50 mM of KCl; 5 mM of
MgCl2; 300 mM each of deoxyadenosine triphosphate, deoxycytidine tri-
phosphate, deoxyguanosine triphosphate; 600 mM of deoxyuridine tri-
phosphate; 0.625 U of AmpliTaq Gold DNA polymerase; and 0.25 U of
uracil N-glycosylase. Amplification was performed using 1 cycle at 50˚C
for 2 min and 1 cycle at 95˚C for 10 min followed by a two-step PCR
procedure consisting of 50 cycles of 15 s at 95˚C and 1 min at 60˚C. PCR
amplification was performed using the ABI Prism 7500 Sequence Detector
System (Applied Biosystems). The normalized value of the SIV proviral
DNA load was calculated as SIV DNA copy number/Macaque albumin
gene copy number3 2 3 106 and expressed as the number of SIV proviral
DNA copies per 106 mononuclear cells.
Neutralization assays
Neutralization was measured as a reduction in luciferase reporter gene
expression after a single round of infection in TZM-bl cells as described
previously (30). TZM-bl cells were obtained from the National Institutes of
Health AIDS Research and Reference Reagent Program. Virus was incu-
bated with serial 3-fold dilutions of samples in duplicate. Freshly trypsi-
nized cells were added to each well. One set of control wells received cells
and virus (virus control), and another set received cells only (background
control). After the 48-h incubation, cells were transferred to 96-well black
solid plates (Costar) for measurements of luminescence. Neutralization
titers are the dilution at which relative luminescence units were reduced by
50% compared with that in virus control wells after subtraction of back-
ground relative luminescence units. Values are considered positive for
neutralizing Ab activity based on the criterion of .33 the observed
background against a negative control simian virus amphotropic murine
leukemia pseudovirus (SVA-MLV) or signal detected in the sera from
control unvaccinated animals, whichever is higher. Assay stocks of mo-
lecularly cloned Env-pseudotyped viruses SIVmac251.6, SIVmac251.30,
SIVsmE660CR54-PK2A5, and SVA-MLV were prepared by transfection in
293T cells and were titrated in TZM-bl cells. The SIVmac251 challenge
stock that had been expanded on rhesus PBMCs and titered in vivo was
obtained from Nancy Miller, Division of AIDS, National Institute of Al-
lergy and Infectious Diseases, National Institutes of Health.
ADCC assay
ADCC was assessed in serum samples collected 2 wk after the final vac-
cination. The rapid and fluorometric–ADCC assay was performed as
previously described using human PBMCs as effectors. SIVmac251 gp120-
coated CEM.NKr cells were used as target cells, with an effector to target
ratio of 50:1 (31). Serial dilutions of serum were evaluated and the ADCC
titer defined as the reciprocal serum dilution at which the percent killing is
greater than that of the mean of control samples plus 3 SDs. The ADCC
activity as measured by this assay does include activity through trogocy-
tosis as also described by others (32).
Western blot
Expi293F cells were transfected with pCDNA5 FRT TO plasmids
expressing either M766 or CG7V gp120 or FLSC using the Expi293
expression system (Life Technologies). Media were collected and clar-
ified by centrifugation at 2 d posttransfection. The clarified supernatants
were subjected to SDS-PAGE under reducing conditions on a Bis-Tris
4–12% NuPAGE gel (Life Technologies) in 13 MOPS buffer. The
proteins were transferred to a polyvinylidene difluoride membrane and
detected using sheep anti–HIV-gp120 D7324 Ab (Aalto Bio Reagents,
Dublin, Ireland) and an alkaline phosphatase–conjugated donkey anti-
sheep secondary Ab. BCIP/NBT solution (Kirkegaard & Perry Laboratories,
Gaithersburg, MD) was used to visualize the alkaline phosphatase–
conjugated secondary Ab.
Binding to rhesus CCR5 peptide by ELISA
High-binding 96-well plates were coated overnight with 1 mg/ml strepta-
vidin or Galanthus nivalis lectin (GNL). Plates were then blocked with
blocking buffer (5% w/v BSA in 13 TBST) for 1 h. Saturating concen-
trations of biotinylated sulfonated (RhR5-S2) and unsulfonated (RhR5)
peptide representing the N-terminal sequence of CCR5 were then added to
the streptavidin plate. rhFLSC or gp120 proteins derived from SIVmac251
and SIVsmE543 transmitted/founder strains M744 and CG7V, respectively,
were added at 1 mg/ml. Bound proteins were detected with antisera derived
from macaques infected with SIVmac251 or SIVsmE543 followed by
HRP-conjugated goat anti-monkey IgG. Between steps, the plates were
washed 33 with 400 ml/well with 13 TBS with 0.1% Tween 20 (TBST) in
an automated plate washer. Amount of bound protein was shown as ab-
sorbance at 450 nm.
Avidity index capture ELISAs
High-binding plates were coated with 1 mg/ml D7324 Ab (Aalto Bio
Reagents) overnight at 4˚C. The plates were washed 33 with 400 ml/well
with 13 TBST in an automated plate washer, blocked with blotto buffer
(5% w/v nonfat milk in 13 TBST) for 1 h, and washed again as before.
SIVmac239 gp130 was added to the plates at 1 mg/ml, incubated for 1 h,
and washed again. Test sera serially diluted in blotto buffer were added
to the assay plates for 1 h. After washing, the wells were incubated for
30 min in 1.5 M sodium thiocyanate (NaSCN; Sigma Aldrich) or 13 PBS
and washed again. HRP-conjugated goat anti-monkey Ab (KPL) was
added at 1:1000 and incubated for 1 h. The plates were washed as before
and incubated in SureBlue TMB Microwell Peroxidase Substrate (KPL)
for 10 min. The reaction was stopped with 1 N H2SO4, and the plates
were read on a spectrophotometer at 450 nm. The avidity index was
calculated by taking the ratio of the NaSCN-treated plasma to the PBS-
treated plasma.
Binding Abs to Fcg receptors
High-binding plates were coated overnight at 4˚C with 2 mg/ml of
SIVmac239 gp130. The plates were washed 33 with 400 ml/well with
13 TBST in an automated plate washer, blocked with blotto buffer for
1 h, and washed again as before. Test sera serially diluted in blotto
buffer were added to the assay plates for 1 h. Biotinylated Fcg receptor
(FcgR; Sino Biological, Beijing, China) was preincubated for 30 min
with HRP-conjugated poly streptavidin (Life Technologies) at final
concentrations of 0.3 and 0.8 mg/ml, respectively. After washing, the
FcgR-poly streptavidin mixture was added to the plates for 1 h. The
plates were washed as before and incubated in SureBlue TMB
Microwell Peroxidase Substrate (KPL) for 10 min. The reaction was
stopped with 1 N H2SO4 and the plates were read on a spectropho-
tometer at 450 nm.
Ab binding to FLSC, gp120, and SIVmac251 peptides
Capture ELISAs were performed as described earlier excluding incubation
with NaSCN. In brief, plates were coated overnight with the D7324 capture
Ab. After blocking, the plates were incubated with the indicated protein Ag
(i.e., M766 and CG7V gp120 or FLSC). Serially diluted test sera were added
to the coated/captured plates, and bound Ab was detected with HRP-
conjugated goat anti-monkey Ab (KPL). HRP was detected using a col-
orimetric TMB reaction as described earlier.
Similarly, the Ab response to overlapping peptides spanning gp120 was
determined by ELISA. A serial dilution of plasma was added to microtiter
plates coated with individual peptides, and the titer was determined. The
absorbance at OD450 nm is reported for peptide mapping.
Ab binding to scaffolded V1/V2 in blood
Binding response for gp70-SIV V1V2 scaffolds was evaluated using a
custom SIV binding Ab multiplex assay performed as previously described
(33, 34). In brief, gp70-SIV V1V2 scaffold proteins (produced by
Dr. Abraham Pinter’s laboratory) were covalently coupled to carboxylated
fluorescent beads (Luminex, Austin, TX). Ag-coupled beads were incu-
bated with serially diluted serum samples, and after washes, subsequently
incubated with biotinylated goat anti-monkey IgG (Rockland Immuno-
chemicals, Limerick, PA). Beads were then washed and acquired on a Bio-
Plex instrument (Bio-Rad, Hercules, CA), and mean fluorescence intensity
(MFI) values were obtained for binding of each sample to each Ags
coupled to the beads. MFI of binding to the gp70 backbone (MuLV gp70)
was subtracted from the MFI of each gp70-SIV V1/V2 scaffold. Anti-SIV
V1V2 levels are shown as MFI area under the curve computed over the
dilutions series.
2728 EFFICACY OF ALVAC-SIV PRIME gp120/FLSC BOOSTED VACCINES
 at U
niversità degli studi di M
ilano on January 4, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
Ab binding to cyclic V2 peptides
Ninety-six-well Immuno 2U-bottom ELISA plates were coated overnight at
4˚C with 100 ml of 2 mg/ml streptavidin (Sigma-Aldrich) in bicarbonate
buffer, pH 9.6, followed by 100 ml of 1 mg/ml biotinylated cyclic V2 (cV2)
peptide (synthesized by JPT Peptide Technologies) for 1 h at 37˚C and
then blocked with blocking buffer (0.5% milk in 13 PBS, 0.1% Tween 20,
pH 7.4) overnight at 4˚C. The contents were then dumped, and 100 ml of
serum samples diluted in blocking buffer was added. Serum was initially
diluted 1:100 in blocking buffer and then serial 2-fold dilutions were
performed and added to wells for 1 h at room temperature. Wells were
washed four times with wash buffer (PBS with 0.1% Tween 20, pH 7.4)
using an automatic plate washer (BioStack washer, BioTek Instruments),
and HRP-conjugated affinity-purified goat anti-monkey IgG (1:1000 in
blocking buffer; The Binding Site) was added to wells for 1 h at room
temperature. Plates were washed four times with wash buffer, 100 ml/well
ABTS substrate was added, and color was allowed to develop at room
temperature for 1 h in the dark. Plates were read at A405nm using an
ELISA reader SpectraMax Plus (Molecular Devices). The data are
expressed as end-point titers, with the titers being defined as the reciprocal
of the highest dilution that yielded an absorbance value greater than twice
the background value (wells that did not contain peptides).
SIV V2 peptide was synthesized by JPT Peptide Technologies GmbH,
Berlin, Germany. The peptide was allowed to fold and cyclize under ther-
modynamic control at high dilution, and the purity was determined to be
.90% by high-performance liquid chromatography and mass spectrometry.
The amino acid sequence of the SIV V2 peptide is based on the SIVsmE543-3
V2 domain from GenBank, accession number U72748. The SIV V2
peptide sequences contain an N-terminal biotin tag. The sequences are as
follows: GF SIVsmE543: CIKNNSCAGLEQEPMIGCKFNMTGLKRDKKIEY-
NETWYSRDLICEQPANGSESKCY; and GF SIVmac251 full: CIAQNNCTGLE-
QEQMISCKFNMTGLKRDKTKEYNETWYSTDLVCEQGNSTDNESRCY.
Reagents and surface plasmon resonance
CM5 chips and the BIAcore amine coupling kit were purchased from GE
Healthcare (Piscataway, NJ). Streptavidin was purchased from Invitrogen
(Grand Island, NY). Affinity-purified goat anti-monkey IgG (g-chain) Ab
was purchased from Rockland Immunochemicals (Gilbertsville, PA).
Surface plasmon resonance measurements were conducted with a
BIAcore T200 using the CM5 chip. Streptavidin was immobilized onto the
chip using the amine coupling kit as directed by the immobilization wizard
packaged within the T200 control software. A total of 6700 response units
(RU) of 1 mM of streptavidin in 20 mM of sodium formate, pH 4.2 (10-min
contact time, 10 ml/min flow rate) was immobilized. The biotinylated
peptide was prepared at a concentration of 1 mM in 20 mM of TRIS, pH
7.4, and allowed to flow (at 10 ml/min) over the streptavidin-coated surface
of flow cell 4 until 3500 RU of SIV V2 peptide was captured.
The mucosal swabs were thawed on ice and centrifuged at 16,100 relative
centrifugal force, 4˚C, for 5 min. The supernatant was diluted 10-fold in
TBS, pH 7.4, and then analyzed on the BIAcore. The diluted mucosal
samples were passed over the chip surface at a flow rate of 30 ml/min for
3 min, followed by a 5-min dissociation period. At the end of the 5-min
period, a 20 mg/ml solution of affinity-purified g-chain–specific goat anti-
monkey IgG Ab was passed over the peptide-coated Ig-bound surface for
2 min at a flow rate of 10 ml/min. After a 70-s dissociation period, the chip
surface was regenerated and data analyzed as previously described using
the BIAevaluation 4.1 software (35). The reported response units (RU) for
the IgG-specific values are the difference between the average value of a 5-s
window taken 60 s after the end of the anti-IgG injection and the average value
of a 5-s window taken 10 s before the beginning of the anti-IgG injection. The
data (RU) are presented for individual mucosal samples.
Chemstrips were used to determine the blood contamination in mucosal
samples. Ten microliters of the mucosal supernatant sample was spotted
onto a Chemstrip 5 OB Urine Test Strip. After 60 s, any change in color was
recorded for comparison with the manufacturer’s color chart.
Phagocytosis
Phagocytosis was measured using methods based on those of Hartshorn
et al. (36) and Huber et al. (37). SIVmac251 virus stock was concentrated
with Lenti-X Concentrator (Clontech, Mountain View, CA) according
to the manufacturer’s protocol and resuspended in complete medium
(RPMI 1640 supplemented with 10% FBS and penicillin-streptomycin
L-glutamine. FITC-labeled virus was prepared as described previously
(36). In brief, concentrated virus stock was incubated with FITC at a
10:1 (virus/FITC) ratio by volume for 1 h and dialyzed overnight
against PBS. FITC-labeled virus was stored in single-use aliquots in
liquid nitrogen until use.
FITC-labeled virus (10 ml based on previous titration, data not shown)
was incubated in screw cap Eppendorf tubes with heat-inactivated serum
from preimmunized and week 26 samples (1:100 final dilution) in com-
plete medium for 1 h at 37˚C in 250 ml of total volume. After 1 h, tubes
were spun at 21,9203 g at 4˚C for 1 h. Without touching the bottom of the
tube, the top 200 ml of supernatant from each tube was removed and
discarded. Two hundred microliters of fresh complete medium was added
to each tube and vigorously vortexed. One hundred microliters from each
tube was dispensed into duplicate wells of a 96-well round-bottom
microtiter plate. One hundred microliters of complete medium was added
to two separate wells to serve as the cell only control. One hundred mi-
croliters of THP-1 cells (20,000 cells) was added to each well and the plate
was incubated for 1 h on an orbital shaker at 37˚C. After 1 h, cells were
washed three times with PBS, trypsinized to remove bound but not inter-
nalized FITC-labeled virus, and resuspended in 150 ml of 4% paraformal-
dehyde. The microtiter plate was stored at 4˚C in the dark overnight. The
next day, the entire volume of each well was transferred to snap cap
Eppendorf tubes and read on an Accuri C6 flow cytometer using CFlow Plus
software. Data were collected and analyzed by setting the FL1 gate at ,1%
for the cell only control (Supplemental Fig. 1). A phagocytic index was
obtained by multiplying the percent positive cells by the median MFI as
previously described (38). The net phagocytic index is reported and was
obtained by subtracting the mean of the indices from a pool of 16 pre-
immunized serum samples.
Intracellular cytokine assay
Mononuclear cells from bloodwere isolated and viably cryopreserved. Cells
were thawed, rested overnight, and 2 3 106 cells were stimulated with
2 mg/ml cognate peptides for 6 h in RPMI 1640 containing 10% human
serum in the presence of 5 mg/ml brefeldin A (Sigma-Aldrich). Non-
stimulated cells, as well as cells stimulated with superantigen (staphylo-
coccal enterotoxin A + staphylococcal enterotoxin B; Sigma-Aldrich),
were used as controls. These cells were then stained with the following
surface markers for 15 min at 4˚C: CD4 (clone L200-PerCP-Cy5.5; BD
Biosciences), CD8 (CD8–PE–Texas Red [ECD]; Cedarlane), CD95 (clone
DX2-PE-Cy5; BD Biosciences), CD28 (clone CD28.2-Pacific Blue,
custom-made; BD Biosciences), CCR7 (clone 3D12-PE-Cy7; BD Biosci-
ences), and PD-1 (clone MIH4-FITC; BD Biosciences). Cells were fixed
for 10 min in 100 ml of 2% paraformaldehyde at room temperature (25˚C).
To stain cells with Abs specific for intracellular cytokines (IFN-g–Alexa-
700, IL-2–allophycocyanin, TNF-a–PE; BD Biosciences), we incubated
the cells with Abs in 0.25% saponin (Sigma-Aldrich) for 30 min at 25˚C
and analyzed them using the BD LSRII flow cytometer. Between 250,000
and 1 3 106 events were acquired for each condition. Data were then
analyzed using DIVA software (BD Biosciences), and the frequency of
cytokine-producing T cells is presented.
Statistical analysis
The Mann–Whitney–Wilcoxon test for continuous factors was used to
compare groups. Correlation analyses were performed using the Spear-
man rank correlation method with exact permutation p values calculated.
Significant differences between the FLSC group and the gp120 group in
the binding of each of the 89 overlapping gp120 peptides were tested
using the exact Mann–Whitney–Wilcoxon test, with the p values cor-
rected for multiple comparisons by the Hochberg method. Because of the
stringency of the correction, uncorrected p , 0.001 was taken as the
cutoff for significance, corresponding to corrected p , 0.056. Peptide
breadth was defined as the number of peptides in each group with an
absorbance greater than background (0.058), and the difference was
evaluated using McNemar test. Increased magnitude was defined as the
number of peptides with a difference in median binding .0.25 and tested
against the binomial distribution with a null proportion of 50% in each
group. The number of challenges administered before SIV acquisition
was assessed using the score test of the discrete-time proportional haz-
ards model. Graphical analysis was performed using GraphPad Prism.
Arithmetic or geometric means are shown on graphs and error bars
represent the SE.
Ethics
All animals were housed and cared for under the guidelines of the Asso-
ciation for the Assessment and Accreditation of Laboratory Animal Care,
the Office of Laboratory Animal Welfare, and the U.S. Department of
Agriculture. The study was conducted with the approval of the Institutional
Animal Care and Use Committee at Advanced BioSciences Laboratories
(protocol no. 491). Animals were closely monitored by the staff veteri-
narian, and several steps were taken to prevent or alleviate suffering; these
included pair housing during the vaccination phase of the study and close
The Journal of Immunology 2729
 at U
niversità degli studi di M
ilano on January 4, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
monitoring specifically following study-related procedures such as rectal or
lymph node biopsies and after SIV infection.
The following steps were implemented should animals exhibit some pain
or discomfort during or after biopsy procedures. Animals will be treated
with buprenorphine (0.01–0.05 mg/kg body weight, intramuscular) for 12–
96 h after surgery to ease pain and discomfort. Other analgesic agents
(such as butorphanol 0.1–0.2 mg/kg, fentanyl 5–10 mg/kg) may be used at
the discretion of the veterinarian. Tylenol (acetaminophen) (80 mg) may
also be used for pain for minor problems such as trauma. Ketofen (keto-
profen) (5 mg/kg) or Banamine (flunixin meglumine) (1–2 mg/kg) is also
used occasionally for pain associated with inflammation. Antibiotics such
as ampicillin or amoxicillin (10 mg/kg) and cephalexin (25 mg/kg) are also
given postsurgery. Appetite, drinking, and behavior are observed closely
for at least 1 wk after surgery. In some instances, SIV-infected macaques
may develop a marked drop in blood CD4+ T cells, severe weight loss,
diarrhea, and so on. These animals may also acquire opportunistic infec-
tions caused by the drop of CD4+ T cells. An animal that is not responsive
to treatment may constitute an end point as determined by the Advanced
BioSciences Laboratories veterinarian.
Humane euthanasia criteria end points included diarrhea, inappetence,
and/or weight loss (.20%, with reduced body condition), as well as tumor,
infection, injury, neurologic signs, behavioral abnormality, or other con-
dition that results in pain, distress, or a significant compromise to the
animal’s well-being and cannot be alleviated by appropriate treatment. If
any end point was reached, animals would be euthanized with an overdose
given i.v. of a barbiturate euthanasia agent.
Results
Study design and antigenicity of the monomeric gp120 and the
FLSC proteins
Rhesus macaques were vaccinated with ALVAC expressing SIV
genes gag-pro and gp120TM at weeks 0, 4, 12, and 24 and given
bivalent boosts with SIVmac251-M766 and SIVsmE660-CG7V gp120
or rhFLSC in alum at weeks 12 and 24 (Fig. 1A).
The expression of both the gp120 and the FLSC proteins was
analyzed by Western blot, and as expected, the FLSC protein had a
higher m.w. than the monomeric gp120 (Fig. 1B). The antigenicity
of these proteins was evaluated by assessing binding to GNL and a
CCR5 peptide (Fig. 1C). As expected, both gp120 and FLSC
proteins bound to GNL; however, only the FLSC protein dem-
onstrated robust binding to a sulfonated CCR5 peptide (Fig. 1C).
Binding to the CCR5 peptide confirms that a correctly folded
FLSC protein was expressed, and that the gp120/CD4 interaction
exposes the coreceptor binding site more efficiently than mono-
meric gp120.
FLSC and monomeric gp120 induce Abs with qualitatively
different binding profiles
We compared the Ab response in ALVAC-SIV primed gp120 or
FLSC-boosted animals by measuring binding Abs in serum 2 wk
after the last vaccination (Fig. 2). Both groups developed equiv-
alent high-titer binding Abs to monomeric gp120-M766 and
gp120-CG7V (Fig. 2A). As expected, sera from the FLSC boosted
animals had significantly higher titers of binding Abs that recog-
nized the FLSC-M766 and the FLSC-CG7V immunogens com-
pared with the monomeric gp120 boosted animals p , 0.0001
(Fig. 2B). The comparison of each animal’s binding titer to the
FLSC-immunogen versus the gp120-immunogen gives an indi-
cation of the abundance of FLSC-specific Abs. Indeed, the FLSC/
gp120 ratio was significantly higher in the FLSC group compared
with the gp120 group: p , 0.0001 (Fig. 2C). This difference was
not due to reactivity to the CD4 protein that is part of the FLSC
immunogen because no seroreactivity was detected against CD4
alone (data not shown).
FIGURE 1. Vaccination regimen and antigenicity of the FLSC proteins. (A) Schematic of the vaccination regimens used in this study. Vaccinated animals
were all given ALVAC-SIV vaccines at weeks 0, 4, 12, and 24 and then boosted with either monomeric gp120 or FLSC proteins at weeks 12 and 24. Control
animals were either naive or given an adjuvant at weeks 12 and 24. At week 28 all vaccinated animals and controls were given a low-dose SIVmac251
intrarectal challenge, which was repeated weekly for up to 10 wk based on SIV status. Asterisk refers to the fact that the boost at week 24 in the FLSC arm
contained 50 mg of FLSC-M766 and 150 mg of FLSC SIV239 pw/eis. (B) Western blot showing the size of monomeric gp120 and FLSC proteins. 293 cells
were transfected with plasmids expressing gp120-CG7V, FLSC-CG7V, gp120-M766, or FLSC-M766. Cells/media were harvested and immunoblotted with
SIVmac251+ sera or SIVsmE660+ sera. (C) ELISA showing binding of gp120 and FLSC proteins from M766 and CG7V binding to GNL, a CCR5 peptide
(RhR5), and a sulfonated CCR5 peptide (RhR5-S2). Both gp120 and FLSC bind to GNL, whereas only rhFLSC proteins bind to the sulfonated CCR5
peptide, indicating that an appropriately folded CD4-gp120 complex is expressed that reveals the coreceptor binding site.
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Next, we assessed Ab recognition of overlapping linear peptides
spanning the variable and constant regions of gp120 (Fig. 2D).
ALVAC-SIV/gp120 vaccination of macaques, similar to ALVAC-
HIV/gp120 vaccination in humans, induces recognition of C1, V2,
V3, and C5 regions of gp120 (39). FLSC boosting significantly
increased the magnitude of Ab recognition (p = 0.0005), assessed as
peptides with differences in median absorbance .0.25. Similarly,
the FLSC group demonstrated increased Ab breadth, with a greater
number of peptides recognized relative to the gp120 group. The
binding to each peptide in the two vaccination regimens was eval-
uated using the Z statistic of the Mann–Whitney–Wilcoxon test
with the Hochberg method used to correct for multiple comparisons
(Fig. 2E). Twenty-two peptides were differentially recognized; the
FLSC group demonstrated better Ab binding to 17 peptides relative
to the gp120 group (Table I). Of the 17 peptides, 6 mapped to the
C3 and V3 domains. Abs to the a2 helix of the C3 domain corre-
lated with vaccine-induced protection from SIVsmE660 (34). Over-
lapping peptides 57, 58, and 59 used in this study contain the
analogous C3 a2 helix of SIVmac251 and were all significantly better
recognized in the FLSC group compared with the gp120 group: p,
0.0001, p = 0.0004, and p = 0.0021, respectively (Table I).
The V3 loop of gp120 is essential for coreceptor binding and
determines CCR5 usage in HIVand SIV (40–43). Analogy with the
HIV gp120 CCR5 binding domain (16, 44, 45) indicates that the
V3 region CRR. . .SGLVF. . .QAWC of SIVmac251 contributes to
CCR5 binding. In addition, an L→W mutation in the SGLVF
sequence confers CXCR4 usage to a SIVmac239 variant (45). The
FLSC group had greater binding Abs to peptides 49 and 51 (p ,
0.0001 and p = 0.053) that together contain the CRR. . .SGLVF
sequence (Table I). Thus, FLSC boosting significantly increased
Ab recognition of epitopes that may be important for virus control.
The FLSC protein boost induces Abs with improved breadth of
neutralization and increased ADCC
We next investigated whether the FLSC boosting affected Ab
function and we used a panel of SIV strains that vary in their
sensitivity to neutralization to assess the in vitro neutralization
capacity of the sera from vaccinated macaques. We found that Abs
induced by both the gp120 and the FLSC regimens similarly
neutralized the tier-1–like (“easy to neutralize”) SIVmac251.6
viruses (Fig. 3A, left panel). In contrast, only the FLSC boosted
animals also neutralized a tier-2–like (“difficult to neutralize”)
FIGURE 2. ALVAC-SIV–primed FLSC boosted animals have increased recognition of gp120 peptides. (A) Binding Ab titers to monomeric gp120
proteins in ALVAC-SIV/gp120 and ALVAC-SIV/FLSC–vaccinated animals measured in serum 2 wk after the last vaccination. (B) Binding Ab titers to the
FLSC immunogen in vaccinated animals measured in serum 2 wk after the last vaccination. Significantly higher binding was observed in the ALVAC-SIV/
FLSC group compared with the ALVAC-SIV/gp120 group measured by the Mann–Whitney–Wilcoxon test with a p value ,0.0001 for both proteins. (C)
All data for the ALVAC-SIV/gp120 group have been previously reported (24). Ratio of Abs binding to the FLSC immunogen versus the monomeric gp120
immunogen (FLSC/gp120). This ratio demonstrates the abundance of FLSC-specific Abs. It was significantly higher in the ALVAC-SIV/FLSC group
compared with the ALVAC-SIV/gp120 group evaluated by the Mann–Whitney–Wilcoxon test with p values,0.0001 for both proteins. (D) Peptide binding
to 89 overlapping linear peptides that span SIVmac251 gp120. Shown is the average binding measured as absorbance to animals in the ALVAC-SIV/FLSC
group on top and the ALVAC-SIV/gp120 group on the bottom. The constant regions of gp120 are shown in black and/or white bars, whereas the variable
loops are in color (E). Comparative recognition of overlapping peptides presented as the difference between the median absorbance in the ALVAC-SIV/
FLSC group, relative to the ALVAC-SIV/gp120 group, is shown in red on the right y-axis. The statistical significance of the differences is shown by the Z
statistic of the Mann–Whitney–Wilcoxon test in black, on the left y-axis, with the dashed lines marking significance at the p , 0.056 level after a
stringent correction for multiple comparisons by the Hochberg method. Increased recognition by the ALVAC-SIV/FLSC group is presented as positive
(0–6) on the top half of the graph, whereas increased recognition in the ALVAC-SIV/gp120 group is presented as negative (26 to 0) on the lower half of
the graph.
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SIVsmE660 virus (Fig. 3A, middle panel), with a significant difference
in neutralization capacity (p , 0.0001) observed between the FLSC
and gp120 groups. Animals boosted with FLSC demonstrated sig-
nificantly higher neutralization ID50 values for the SIVmac251 chal-
lenge virus, p , 0.0001, although only 2 of the 53 vaccinated
animals (both in the FLSC group) were above the cutoff level of the
assay (Fig. 3A, right panel). None of the vaccinated animals neu-
tralized a tier-2–like SIVmac251.30 isolate (data not shown).
High-avidity nonneutralizing Abs can prevent or control in-
fection via Fcg-mediated interactions with macrophages and NK
cells. Thus, we compared binding to the FcgR (CD16), ADCC,
phagocytosis, and avidity of Abs in the two vaccinated groups.
FLSC significantly increased Ag-specific Abs that could bind to
recombinant FcgR3a-CD16 (p = 0.014; Fig. 3B), whereas binding
to recombinant FcgR2a and FcgR1 was similar in the FLSC and
gp120 groups (data not shown). NK cells expressing FcgR3a can
coordinate with Abs in the killing of infected cells. FLSC boosting
also significantly increased the titer of Abs mediating ADCC (p ,
0.0001; Fig. 3C) and increased maximum killing of gp120-coated
target cells compared with the gp120 group (p , 0.0001, data not
shown). Titers of Ag-specific Abs bound by recombinant FcgR3a
were directly correlated with ADCC titer (r = 0.38, p = 0.005).
Both vaccination regimens induced Abs that facilitated equivalent
phagocytosis by the THP-1 cell line of FITC-labeled SIV virus
and bound gp120 with similar avidity (Fig. 3D, 3E).
Serum Abs to the gp120 V2 region decrease the risk of
SIVmac251 acquisition
Reduced risk of HIV acquisition in the RV144 trial was correlated
with serumvaccine-induced bindingAbs to theV1/V2 region of gp120
(2, 46). V2 reactivity in the RV144 trial was tested using the V1/V2
loops fused to the murine leukemia virus gp70 (gp70-V1/V2), linear
peptides spanning the V2 loop, as well as V2 peptides cyclized by
disulfide bonds (39, 47). ALVAC-HIV/gp120 vaccines induced two
potentially distinct V2 Ab responses: one directed to a conforma-
tional V1/V2 epitope measured by the gp70-V1/V2 scaffold, and the
other to a linear epitope in V2 proximal to the putative a4b7 binding
site (47). Using similar reagents constructed with SIVmac251 and
SIVsmE543 variable loop sequences, we measured serum binding Ab
levels to gp70-V1/V2 proteins, cV2, and linear V2 peptides at 2 wk
after the last vaccination. ALVAC-SIV–primed FLSC-boosted ani-
mals had significantly higher levels of gp70-V1/V2–directed Abs
(p = 0.033; Fig. 4A). Fig. 4B shows the V2 sequence used to measure
serum Ab binding to 10 overlapping linear peptides that spanned the
V2 region. The FLSC group demonstrated significantly better rec-
ognition of peptide 24 that spans the first third of the V2 loop,
compared with the gp120 group (p = 0.013, Supplemental Fig. 2A).
The second half of the V2 loop designated (V2b) spans peptides 26–
28 and contains the region proximal to the putative a4b7 binding
site. The majority of animals recognized the V2b region, and the
magnitude of the response did not differ between the monomeric
gp120 and the FLSC groups (Supplemental Fig. 2B).
To confirm V2 reactivity, we compared binding Abs with cV2
peptides from SIVmac251 and SIVsmE543 in serum and rectal se-
cretions. We found significantly higher SIVsm-cV2 responses in
the serum of FLSC boosted animals compared with the gp120
group (p = 0.0001; Fig. 4C). A nonsignificant increase in serum
SIVmac251 cV2 responses was also observed in the FLSC group
(p = 0.074; Fig. 4C). Similarly, a nonsignificant increase in rectal
cV2 Abs was observed in the FLSC group, directed to both SIVmac251
and SIVsmE543 Ags (Fig. 4D).
We next assessed vaccine efficacy by comparing the rate of
intrarectal acquisition over the course of 10 weekly intrarectal ex-
posures to SIVmac251 virus in vaccinated and unvaccinated animals.
Animals were challenged with 120 TCID50 of SIVmac251, a dose that
infects an average of 37% of the controls at each exposure. Seven
days after SIV exposure, we measured SIV RNA in plasma by
nucleic acid sequence-based amplification, and animals with ,50
copies/ml at that time were considered SIV2 and rechallenged. This
study was powered to compare SIV acquisition between vaccinees
and controls, but not to compare the rate of SIVacquisition between
the two vaccine groups. As demonstrated previously, vaccination
with ALVAC-SIVand monomeric gp120 significantly decreased the
rate of SIVacquisition compared with controls (p = 0.020; Fig. 4E),
with an estimated vaccine efficacy rate of 44% at each mucosal
challenge (24). ALVAC-SIV–primed FLSC boosted animals dem-
onstrated a decreased SIVmac251 acquisition rate compared with con-
trols, which approached, but did not attain, statistical significance
Table I. Differential recognition of peptides by ALVAC-SIV/gp120 and ALVAC-SIV/FLSC vaccines
Peptide Sequence Region Is Greater Than p Value
15 PCVKLSPLCITMRCNKSETD V1 FLSC . gp120 0.053
20 ITTAAPTSAPVSEKIDMVNE V1 FLSC . gp120 0.024
24 IAQNNCTGLEQEQMISCKFT V2 FLSC . gp120 0.013
34 NTSVIQESCDKHYWDTIRFR C2 FLSC . gp120 0.0013
46 NRTYIYWHGRDNRTIISLNK C2 FLSC . gp120 0.046
47 WHGRDNRTIISLNKYYNLTM C2 FLSC . gp120 ,0.0001
49 NKYYNLTMKCRRPGNKTVLP C2/V3 FLSC . gp120 ,0.0001
51 PGNKTVLPVTIMSGLVFHSQ V3 FLSC . gp120 0.0530
57 WKDAIKEVKQTIVKHPRYTG C3 FLSC . gp120 ,0.0001
58 EVKQTIVKHPRYTGTNNTDK C3 FLSC . gp120 0.0004
59 VKHPRYTGTNNTDKINLTAP C3 FLSC . gp120 0.0021
61 DKINLTAPGGGDPEVTFMWT C3 FLSC . gp120 0.0560
66 MNWFLNWVEDRDVTTQRPKE V4 FLSC . gp120 0.039
68 VTTQRPKERHRRNYVPCHIR V4 FLSC . gp120 ,0.0001
76 TSLIANIDWTDGNQTSITMS V5 FLSC . gp120 0.015
78 NQTSITMSAEVAELYRLELG V5 FLSC . gp120 0.0001
79 MSAEVAELYRLELGDYKLVE V5 FLSC . gp120 ,0.0001
33 CYMNHCNTSVIQESCDKHYW C2 gp120 . FLSC ,0.0001
38 PGYALLRCNDTNYSGFMPKC C2 gp120 . FLSC 0.0005
73 KNVYLPPREGDLTCNSTVTS C4 gp120 . FLSC 0.0013
83 GLAPTDVKRYTTGGTSRNKR C5 gp120 . FLSC ,0.0001
89 AMGAASLTLTAQSRTLLAGI C5 gp120 . FLSC ,0.0001
Boldface indicates the region of peptide overlap. The putative CCR5 binding sites in V3 are underlined:
CRR. . .SGLV. . .QAWC.
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(p = 0.089; Fig. 4E), with an estimated vaccine efficacy rate of
34%. Notably, at the end of the challenge phase, that is, 2 wk after
the 10th SIV challenge, three animals in the gp120 group and
three in the FLSC group remained uninfected.
Next, we determined whether any immunologic responses mea-
sured were associated with delayed SIVmac251 acquisition. No
correlation was found with T cell responses; however, delayed
acquisition in both groups was associated with V2 responses. Ani-
mals in each group were dichotomized based on the presence or
absence of a cV2 response in serum or rectal secretions. In the
ALVAC-SIV/gp120 regimen, a decreased rate of SIVacquisition was
observed in animals with mucosal cV2 responses directed to the
SIVsmE543 Ag (p = 0.0018; Fig. 4F, left panel) (24). A similar as-
sociation was not observed with the level of serum CV2 responses
(data not shown). In contrast, in the ALVAC-SIV/FLSC regimen,
serum, but not mucosal, Ab responses greater than the 25th percentile
directed to cV2 or linear V2b peptides were associated with delayed
SIV acquisition; p = 0.0016 and p = 0.008, respectively (Fig. 4F,
middle and right panels, and data not shown). Importantly, the ac-
quisition curves of animals that had Abs to cV2 or V2b differed
significantly from that of control animals (Supplemental Fig. 3A, 3B).
FLSC boosting does not improve T cell responses or
postinfection virus control
The infected vaccinated animals had peak viremia ranging from 106
to109 and set point viremia ranging from 104 to 108 (Fig. 5A, 5B).
Next, we compared the geometric mean SIV plasma virus load
among the gp120 group, FLSC group, and controls, and found no
significant differences in peak or set-point viremia (Fig. 5C). Two to
three weeks post SIV infection we obtained rectal pinch biopsies from
all vaccinated animals and controls, and quantified the level of SIV
DNA per 106 cells. ALVAC-SIV/gp120 vaccines had significantly
lower SIV DNA levels in the rectum compared with the FLSC group
(p = 0.028) but had a nonsignificant reduction in SIV DNA compared
with controls. However, when the SIV DNA levels in all three groups
are compared, there is no significant difference among the FLSC,
gp120, and control groups (p = 0.074; Fig. 5D). One consequence of
robust HIV/SIV virus replication is the loss of CD4+ T cells, a marker
of disease progression. All vaccinated animals and controls had a
progressive decline in CD4+ T cells and lost on average 50–65% of
their CD4+ T cells within the first 12 wk of infection (Fig. 5E).
ALVAC/gp120 vaccination characteristically induces low T cell
responses in humans and nonhuman primates (1, 35). One week
before the first SIV challenge, we stimulated PBMCs with over-
lapping peptides that spanned SIVmac251 Gag or Env and evaluated
the cytokine profile of SIV-specific CD4+ and CD8+ T cells. We
observed negligible anti-Env and anti-Gag CD8+ T cell responses,
no Gag-specific CD4 responses (data not shown), and comparable
Env-specific CD4 T cell responses after the last immunization in
both groups (Fig. 5F). The lack of virus control once infection
occurred is likely due to the limited cell-mediated CD8+ T cell
responses induced by these vaccine modalities.
FIGURE 3. Vaccination with FLSC proteins altered select Ab functions. (A) Serum neutralization of SIVmac251.6 (left), SIVsmE660-CR54-PK-2A5 (middle),
and the SIVmac251 challenge virus stock (right). Neutralization was assessed in TZMbl cells 2 wk postvaccination with gp120 boosted animals in open
circles and the FLSC boosted animals in closed squares. Sera is considered positive if the sample value is .33 the observed background of a control
murine leukemia pseudovirus or unvaccinated controls. Dashed horizontal lines on the graph indicate background levels. Both vaccine groups showed
equivalent neutralization of the tier 1–like SIVmac251.6 isolate, whereas the ALVAC-SIV/FLSC group demonstrated significantly better neutralization of the
tier 2–like SIVsmE660 pseudovirus; p , 0.0001 measured by the Mann–Whitney–Wilcoxon test. The ALVAC-SIV/FLSC group also showed significantly
higher neutralization ID50 values for the SIVmac251 challenge virus, p , 0.0001, although only two animals had values that scored positive, that is, were
greater than the cutoff level of the assay. (B) All data for the ALVAC-SIV/gp120 group in (A) have been previously reported (24). Serum binding Ab titers to
FcgR3a (CD16), the ALVAC-SIV/FLSC group, had significantly higher binding titers relative to the ALVAC-SIV/gp120 group; p = 0.014 evaluated by a
Mann–Whitney–Wilcoxon test. (C) ADCC was measured in serum from vaccinated animals 2 wk after the last vaccination. The ALVAC-SIV/FLSC group
demonstrated significantly higher ADCC titers, p , 0.0001, by the Mann–Whitney–Wilcoxon test. (D) The data for the ALVAC/gp120 group have been
previously reported (24). Equivalent opsonization of FITC-coated SIV virions presented as phagocytic index for the ALVAC-SIV/gp120 group and the
ALVAC-SIV/FLSC group. (E) The avidity of Abs to gp120 presented as avidity index was similar in both groups.
The Journal of Immunology 2733
 at U
niversità degli studi di M
ilano on January 4, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
Discussion
Vaccine-mediated protection from HIV infection appeared an
unachievable goal until 2009, when the results of the RV144 Thai
trial demonstrated that a recombinant ALVAC-HIV vaccine given
with a bivalent gp120 Clade B/E boost could significantly reduce the
risk of HIV acquisition (1). The protective efficacy rate of this
regimen was estimated at 31.2% in a population primarily at low
risk of HIV infection. To date, vaccine efficacy or a lack thereof,
evaluated using mucosal exposure to SIV as a challenge model, has
mirrored the results of all six HIV vaccine efficacy trials in humans
(48–50). In this study, we evaluated relative vaccine efficacy by
using low repeated doses of the pathogenic SIVmac251 propagated in
macaque cells (35). This virus stock is highly genetically diverse,
uses the CCR5 coreceptor, and similar to most primary HIV strains,
is resistant to neutralization. One of the vaccine regimens reported
in this study was designed to model RV144 in macaques and in-
cluded an ALVAC vector expressing SIVmac251 Ags and two boosts
with the two monomeric recombinant gp120 SIVmac251 and SIVsmE660
proteins (24). With this regimen, we observed an estimated vaccine
efficacy of 44% (24) measured as a decreased risk of SIVmac251
acquisition at each mucosal challenge compared with controls
(p = 0.020; Fig. 4E).
In this study, we aimed to improve the Ab breadth and functional
profile induced by the ALVAC/gp120 vaccine by substituting the
monomeric gp120 boosting of ALVAC-SIV–primed animals with
an FLSC protein boost consisting of SIV-gp120 linked to rhFLSC
CD4. Similar to previous studies using HIV-FLSC proteins (21),
we show that SIV-FLSC proteins indeed adopt a conformation
FIGURE 4. FLSC boosting increased Abs directed to the V2 loop of gp120. (A) Serum binding Abs to the gp-70 scaffolded V1/V2 proteins from
SIVmac251WY (left) and SIVsmE660BR (right) measured 2 wk after the last vaccination. Significantly higher Abs are observed in the FLSC boosted animals
compared with the gp120 boosted group evaluated by the Mann–Whitney–Wilcoxon test: p = 0.033 for both proteins. (B) Sequence of the V2 region of
SIVmac251 and the 10 linear overlapping peptides that were used to map V2 responses. The sequence of peptide 24 is bolded. (C) Serum binding IgG titers to
full-length cV2 peptides from SIVmac251 (left) and SIVsmE543 (right) measured 2 wk after the last vaccination. Significantly higher SIVsm cV2 Abs were
seen in the FLSC group versus the gp120 group, p = 0.0001, whereas cV2 Abs to SIVmac251 approached, but did not attain, statistical significance: p = 0.074
measured by the Mann–Whitney–Wilcoxon test. (D) Binding Abs (IgG) in rectal secretions measured as resonance units to the full-length cV2 immunogens
SIVmac251 (left) and SIVsmE543 (right) in vaccinated groups and controls. (E) Rate of SIV acquisition, shown as the percent infected after weekly intrarectal
exposure to SIVmac251. ALVAC-SIV/gp120 vaccinated significantly decreased the rate of SIV acquisition compared with controls (p = 0.02) measured by
the score test of the discrete time proportional hazards model. (F). SIV acquisition in the ALVAC-SIV/gp120 group dichotomized based on the presence or
absence of cV2 Abs (IgG) to SIVsm in the rectal secretions (left panel). Animals with detectable rectal IgG to SIVsm had a slower rate of SIV infection, p =
0.0018, measured by the score test of the discrete time proportional hazards model. In the middle and right panels, animals in each group were dichot-
omized based on whether their serum cV2 or linear V2b peptide response fell above or below the 25th percentile. If the response was below the 25th
percentile, the animals were considered low responders. ALVAC-SIV/FLSC–vaccinated animals with cV2 (middle panel) and V2b responses (right panel)
above the 25th percentile had a slower rate of SIV infection (p = 0.0016 and p = 0.008), measured by the score test of the discrete time proportional hazards
model. The data for the ALVAC-SIV/gp120 group (A and C–F) have been previously reported (24).
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where the coreceptor binding site is exposed and can be bound by
CCR5 peptides (Fig. 1).
ALVAC-SIV–primed FLSC-boosted macaques demonstrated
increased Ab magnitude and breadth compared with animals
boosted with monomeric gp120 (Fig. 2, Table I). Importantly,
FLSC also induced Abs with increased recognition of peptides 49
and 51 that include the putative CCR5 binding domain in the V3
loop of SIV gp120 (Table I). The V3 loop of both HIV and SIV is
critical for coreceptor binding and determines which coreceptor is
used for entry (40–45). A CXCR4 using SIVmac239 variant was
described with three mutations in the V3 loop sequence:
NKTVLPVTIMSGLVF (positions shown in bold). These muta-
tions either conferred or improved CXCR4 usage, demonstrating
the importance of this V3 sequence for coreceptor usage (45). This
identical sequence is present in peptide 51 that showed increased
recognition by the FLSC group, further confirming that FLSC
boosting induced Abs to the coreceptor binding site.
Surprisingly, FLSC-increased immunogenicity including the
induction of Abs directed to the CCR5 binding site, high neu-
tralizing Abs to a tier 2 virus, and increased ADCC (Fig. 3) but did
not result in increased vaccine efficacy. Vaccine efficacy was
significant in the ALVAC-SIV/gp120 group (44%) and not in the
ALVAC-SIV/FLSC group. There was a trend for reduced SIV
acquisition (p = 0.089), and a lower estimated vaccine efficacy
rate of 34% at each mucosal challenge. At the end of the challenge
phase, both vaccine groups had three animals that remained un-
infected. Neither regimen decreased acute or set-point viremia or
curtailed peripheral CD4+ T cell loss (Fig. 5). Similarly, a lack of
virus control was observed in both macaque and human studies
using ALVAC/gp120 regimens that induce limited CD8 responses
(1, 35). FLSC boosting did not improve the T cell response rel-
ative to gp120-boosted animals (Fig. 5F).
In humans, the ALVAC-HIV/gp120 vaccine regimens induced
V2-directed Abs measured by gp70-V1/V2 scaffolds and linear
sequences that mapped to the midregion of V2 proximal to the
a4b7 binding site, and were a correlate of reduced risk of ac-
quisition of HIV (2, 39, 47). Furthermore, V2 Abs to residue 169
exerted immunologic pressure on transmitted viruses, producing a
sieve effect in HIV-infected vaccinees (51). The FLSC boost in-
creased binding Abs directed to the scaffolded gp70-V1/V2, a
linear V2 peptide, and cV2 peptides (Fig. 4). In neither regimen
was the decreased risk of SIV acquisition associated with serum
Abs to the gp70 V1/V2 scaffold, as observed in the RV144 trial in
humans. Rather, serum Abs to both cyclic and linear V2 peptides
were associated with delayed SIV acquisition in the FLSC group
(Fig. 4F). In the monomeric gp120 group it was the mucosal, and
not the serum, Ab response to cV2 that correlated with decreased
risk of SIV acquisition (Fig. 4F) (24). These data suggest that
FIGURE 5. Lack of virus control in ALVAC-SIV–primed gp120 or FLSC boosted infected macaques. (A) SIV plasma virus in ALVAC-SIV/gp120
animals over the course of the study; the geometric mean of all SIV-infected animals is shown in black. Three of 27 animals remained SIV2 (SIV RNA ,
50 copies/ml) over the 13 wk of follow-up. (B) SIV plasma virus in ALVAC-SIV/FLSC animals over the course of the study; the geometric mean of all SIV-
infected animals is shown in black. Three of 26 vaccinated animals remained SIV2 (SIV RNA , 50 copies/ml) over the 13 wk of follow-up. (C)
Comparison of the geometric mean of plasma virus in SIV-infected animals from the gp120 group (red), FLSC group (green), and controls (black). No
difference in peak or set point plasma virus is observed between vaccinated animals and controls. (D) Virus burden in the rectal mucosa measured as SIV
DNA/106 mononuclear cells. Rectal biopsies were obtained 3 wk post SIV infection, and the ALVAC-SIV/gp120 animals are shown in red open circles, the
ALVAC-SIV/FLSC animals in green squares, and the controls in black triangles. A significantly lower level of SIV DNAwas observed in the gp120 group
compared with the FLSC group (p = 0.028), but when both vaccine groups and controls are compared the differences are not significant (p = 0.074). (E)
Percentage of baseline CD4 T cells in the blood over the course of the study. A similar progressive loss of CD4 T cells is observed post SIV infection over
the 12 wk of follow-up in vaccinated animals (red lines, gp120 group; green lines, FLSC group) and controls (black line). (F) Envelope (Env)-specific CD4+
T cell responses measured in PBMCs 1 wk before SIV challenge. Shown is the frequency of IFN-g+, TNF-a+, or IL2+ T cells after stimulation with
overlapping SIVmac251-m766 Env peptides. ALVAC-SIV/gp120–vaccinated animals are shown by circles, whereas ALVAC-SIV/FLSC animals are shown
by squares. A similar frequency of Env-specific CD4 T cells is observed in both groups after background subtraction of unstimulated cells. The data for the
ALVAC-SIV/gp120 group (A and C–F) have been reported previously (24).
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there may be differences in the Ab specificity and function that
populate mucosal sites in animals immunized with these different
Ags. Limitations in samples obtained from the mucosal secretions
prevented the functional characterization of mucosal Abs. It is
also possible that FLSC may induce different protective immune
responses as compared with monomeric gp120 (23).
Apart from increasing binding Abs, boosting the Ab response
with FLSC proteins also increased Ab function (Fig. 3). ADCCwas
a secondary correlate in RV144- (2) and ALVAC-HIV/gp120–
induced Abs directed to the C1 region of gp120 that were potent
mediators of ADCC in vitro (3). Similar ADCC epitopes have not
been defined for SIV, but we were intrigued to find increased
recognition of C1 peptides in the FLSC group and significantly
increased ADCC titer (Fig. 3). However, none of these responses
correlated with a decreased risk of SIVmac251 acquisition.
Neither vaccine regimen induced neutralizing Abs with suffi-
cient breadth and potency to block SIVmac251 entry into target cells
in vitro. It is notable that the FLSC-immunized animals, boosted
with the FLSC-SIVsmE660-CG7V immunogen, derived from a vi-
rus that demonstrates intermediate neutralization resistance (52),
neutralized the resistant pseudovirus SIVsmCR54-PK-2A5 (Fig. 3A).
None of the animals in the gp120 group had Abs that could
neutralize this tier-2–like SIVsm virus. FLSC immunization
also significantly increased binding to the C3 a2 helix region of
SIVmac251 (peptides 57–59; Table I). An Ab response to the C3 a2
helix region of gp120, AIQEVKETLVKHPRYTGT, was signifi-
cantly associated with protection from SIVsmE660 (34). The anal-
ogous a2 helix is a neutralization target in subtype C HIV (53).
Anti-C3 Abs can exert immunologic pressure to reduce HIV vi-
remia, as evidenced by the escape mutations that emerge followed
by virus rebound (53). In this study, however, increased C3 pep-
tide recognition was not associated with delayed SIVmac251 ac-
quisition. It is possible that the FLSC-induced anti-C3 Abs may
prevent the transmission of neutralization-sensitive viruses as
opposed to the neutralization-resistant challenge stock of SIVmac251
used in this study (52).
Our study demonstrates that the FLSC immunogen does improve
Ab function and confirms the importance of Abs targeting the V2
region of gp120 in protection from SIVmac251 infection. However, a
significant vaccine efficacy was observed only in the ALVAC-
gp120 animals boosted with monomeric gp120. One difference
between the groups is that the same gp120 immunogen is present
in the prime and boost of the ALVAC-gp120 group, whereas the
FLSC group contains the gp120 immunogen in the ALVAC-SIV
prime and was given the FLSC immunogen as the boost. In
contrast, a DNA prime-envelope boost regimen that included four
vaccinations with matched FLSC immunogens significantly re-
duced the rate of transmission of the same stock of SIVmac251 (23).
These results suggest that perhaps matching the structure of the
envelope immunogens used to prime and boost the immune sys-
tem may be critical to induce Abs with sufficient potency, speci-
ficity, and breadth to prevent SIVmac251 transmission.
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